The Neurofibromatoses
The neurofibromatoses are a group of autosomal dominant genodermatoses belonging to the neurocutaneous syndromes (phakomatoses). They are characterized by abnormal growth of tissues derived from the neural crest. The group includes clinically and genetically distinct conditions: neurofibromatosis type 1 (NF1, von Recklinghausen disease), NF2-related schwannomatosis (formerly NF2) and schwannomatosis.
Molecular basis:
- NF1 (more than 90% of neurofibromatosis cases): Caused by heterozygous loss-of-function mutations in the NF1 gene on chromosome 17q11.2. This gene encodes neurofibromin, a protein that switches active RAS-GTP to inactive RAS-GDP. Without enough neurofibromin, the RAS-MAPK pathway (RAS-RAF-MEK-ERK) is overactive, driving uncontrolled growth of Schwann cells, fibroblasts and pigment cells.
- NF2 (NF2-related schwannomatosis): Caused by mutations in the NF2 gene on chromosome 22q12.2, which encodes merlin (schwannomin), a tumor suppressor that helps organize the cell's cytoskeleton. Loss of merlin leads to multiple schwannomas in the central and peripheral nervous system.
Skin findings, especially café-au-lait macules (CALMs) and neurofibromas, are the earliest signs. They act as a warning that allows dermatologists to recognize the condition before serious complications develop (optic nerve tumors, bone deformities, malignant transformation).
Clinical Features and Neurocutaneous Signs
The skin and peripheral findings of neurofibromatosis change with age and disease type:
- Clinical Features of Neurofibromatosis Type 1 (NF1):
- Café-au-lait macules (CALMs): Flat, light to dark brown patches with smooth borders that appear in the first year of life and increase in number and size with age.
- Crowe sign: Scattered freckles in skin folds (armpits, groin, under the breasts) that appear around ages 3–5. This is a highly specific clinical sign of NF1.
- Cutaneous and subcutaneous neurofibromas: Soft, pink or skin-colored bumps that show the "buttonhole" sign (they sink into the dermis when pressed). They tend to appear in large numbers at puberty or during pregnancy.
- Plexiform neurofibroma: A large, soft tumor that infiltrates along a nerve, often with hyperpigmented skin or coarse hair over it. It can progress to a malignant peripheral nerve sheath tumor (MPNST).
- Lisch nodules: Yellow-brown hamartomas on the iris, detected by slit-lamp examination.
- Clinical Features of NF2-Related Schwannomatosis:
- Patients have few café-au-lait macules (fewer than 6) and no Lisch nodules.
- The main skin sign is cutaneous schwannomas: slightly thickened, firm plaques or subcutaneous nodules along the course of a nerve.
- Bilateral vestibular schwannomas: Cause tinnitus, hearing loss and progressive balance problems starting in adolescence.
NF1 vs. NF2: Key Differences
| Feature | NF1 (von Recklinghausen) | NF2-Related Schwannomatosis |
|---|---|---|
| Gene and location | NF1 gene (chromosome 17q11.2) | NF2 gene (chromosome 22q12.2) |
| Café-au-lait macules (CALMs) | ≥ 6 macules, smooth borders, appear very early | Uncommon (< 6 macules), small |
| Neurofibromas | Many cutaneous and/or plexiform neurofibromas | None (schwannomas only) |
| Eye and nerve involvement | Lisch nodules of the iris, optic pathway glioma | Bilateral schwannomas of cranial nerve VIII, cataracts |
| Malignancy risk | High (MPNST, pheochromocytoma, brain tumors) | Lower (mainly complications from tumor compression) |
Diagnosis and Clinical Management at Haute-Derma
When we see a patient with multiple café-au-lait macules or suspicious bumps under the skin, Haute-Derma follows a structured diagnostic pathway:
Checking Against the Revised NF1 Diagnostic Criteria (2021 International Consensus)
NF1 is diagnosed when a patient without an affected parent meets 2 or more of the following criteria:
- 6 or more café-au-lait macules (> 5 mm before puberty, > 15 mm after puberty).
- Freckling in the armpits or groin (Crowe sign).
- 2 or more neurofibromas of any type, OR 1 plexiform neurofibroma.
- Optic pathway glioma.
- 2 or more Lisch nodules of the iris OR 2 or more choroidal abnormalities.
- A characteristic bone lesion (sphenoid wing dysplasia, congenital bowing of the tibia).
- A heterozygous pathogenic NF1 gene variant.
- A parent diagnosed with NF1 by these criteria.
Avoid Inappropriate Cosmetic Procedures
- No pigment lasers or IPL on café-au-lait macules before the cause is known: Indiscriminate laser treatment of CALMs in NF1 does not give lasting results, recurrence is common, and it can trigger rebound hyperpigmentation.
- No electrocautery, mesotherapy, RF or cosmetic "mole removal" procedures on neurofibromas: Neurofibromas contain blood vessels and nerve fibers. Improper invasive procedures can cause persistent bleeding, hypertrophic scarring, and burns or injury to peripheral nerve branches.
Skin Biopsy and Molecular Genetic Testing
- Skin (punch) biopsy: Performed when a solitary neurofibroma is suspected of malignant change, or to distinguish a schwannoma (strong, uniform S100 staining) from a neurofibroma (patchy S100 staining with interspersed fibroblasts and mast cells).
- Gene panel testing (NGS): Analysis of the NF1 and SPRED1 genes to reliably distinguish NF1 from Legius syndrome.
Multidisciplinary Screening
- Ophthalmology: Regular slit-lamp examination for Lisch nodules, plus visual acuity and visual field testing to detect optic pathway glioma.
- Imaging: Brain or spine MRI when neurological symptoms are present, and whole-body MRI to assess the burden of plexiform neurofibromas.
- Red flags for malignancy (MPNST): Urgent oncology referral is needed if a plexiform tumor causes sudden sharp pain, grows rapidly, or changes from soft to firm.
